Takeda Pharmaceutical Company Limited
4502
Peringkat dalam Saham
#375
Takeda Pharmaceutical Company Limited is a global biopharmaceutical enterprise... Takeda Pharmaceutical Company Limited is a global biopharmaceutical enterprise engaged in the discovery, development, manufacturing, marketing, and out-licensing of various medical products. The company's operations span Japan, the United States, Europe, Canada, Latin America, Russia, and other regions across Asia and internationally. Takeda concentrates its efforts on key therapeutic areas such as gastroenterology, rare diseases, plasma-derived therapies, oncology, and neuroscience. Its extensive product range includes well-known brands like Entyvio, Takhzyro, Velcade, and Vyvanse. To advance its pipeline and innovation, Takeda actively fosters numerous collaborations, in-licensing agreements, research partnerships, and strategic alliances with a diverse array of organizations, including academic institutions like the University of Texas MD Anderson Cancer Center and biotech firms such as Neurocrine Biosciences, Inc. and Arrowhead Pharmaceuticals Inc. Established in 1781, the company maintains its headquarters in Tokyo, Japan.
Harga Saham
$40.45
Kapitalisasi Pasar
$64.36B
Perubahan (1 hari)
1.19%
Perubahan (1 tahun)
43.11%
Negara
JP
Perdagangan Takeda Pharmaceutical Company Limited (4502)
Kategori
Healthcare
Rasio P/B untuk Takeda Pharmaceutical Company Limited (4502)
Rasio P/B per 2026 TTM: 0
Menurut laporan keuangan dan harga saham terbaru dari Takeda Pharmaceutical Company Limited, rasio P/B saat ini (TTM) adalah 0. Pada akhir 2026, rasio P/B perusahaan adalah 0.
Riwayat rasio P/B untuk Takeda Pharmaceutical Company Limited dari 2026 hingga 2026
Rasio P/B pada akhir setiap tahun
| Tahun | Rasio P/B | Mengubah |
|---|---|---|
| Tidak cukup data untuk tanggal yang disediakan. | ||
Rasio P/B untuk perusahaan sejenis atau pesaing
| Perusahaan | Rasio P/B | Perbedaan Rasio P/B | Negara |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| - | - |
CH
|
|
| 5.041 | - |
IN
|
|
| - | - |
CN
|
